Deutsche Bank Rates Apogee Therapeutics (APGE) hold

Deutsche Bank set a $135 price target for Apogee Therapeutics, downgrading it to a hold rating, a 1.75% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 3:01 PM EDT · Updated Jun 26, 2026, 11:03 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Deutsche Bank rated Apogee Therapeutics, Inc. ($APGE) "hold" with a $135 price target on June 23, 2026.

APGE Apogee Therapeutics, Inc.

$132.65 +75.05% year to date

Daily close · Jun 22, 2026

Key Points

Deutsche Bank downgraded Apogee Therapeutics to a hold rating with a price target of $135 on June 23, 2026.
Deutsche Bank's $135 price target implies 1.75% upside from Apogee Therapeutics, Inc.'s ($APGE) current $132.68 share price.
Shares of NasdaqGM:APGE traded near $132.55 on Tuesday, with a market cap of approximately $9.99 billion.
T. Rowe Price Investment Management increased its holdings by 7,568,528 shares, now holding over 10.3 million shares.

Get $APGE trade alerts by text

We text you when insiders, Congress or big funds trade $APGE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Apogee Therapeutics, Inc. alert may contain errors. Disclosures

Deutsche Bank has downgraded Apogee Therapeutics, Inc. (NasdaqGM: APGE) to a hold rating, setting a price target of $135. This rating change was announced on June 23, 2026, by analyst David Hoang.

Analyst rating track record

Deutsche Bank vs. the S&P 500

YTD return +24.34% hypothetical

All-time return +55.74% S&P 500 +37.07%

vs. S&P 500 +18.67% ahead of the index

Hypothetical returns from Deutsche Bank's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Apogee Therapeutics

T. Rowe Price Investment Management significantly increased its stake in Apogee Therapeutics, adding 7,568,528 shares to hold a total of 10,300,984 shares valued at about $867 million, marking a 277% increase. Meanwhile, FMR LLC also grew its position by 1,037,253 shares, bringing its total to 9,262,291 shares worth approximately $780 million, a 12.6% increase. On the other hand, Wellington Management Group reduced its holdings by 370,882 shares, now holding 4,375,703 shares valued at around $368 million, reflecting a 7.8% decrease. BlackRock, Inc. added 301,657 shares, increasing its stake by 8% to 4,085,651 shares valued at roughly $344 million.

Apogee Therapeutics Stock Snapshot

Shares of Apogee Therapeutics, Inc. traded near $132.55 on Tuesday. The company has a market cap of about $9.99 billion. It is not currently profitable, with a forward P/E ratio calculated at -25.52. The stock has a 52-week low of $34.34 and a high of $133.00. Its 50-day moving average is $84.76, and the 200-day moving average is $69.38. The company maintains a strong liquidity position with a current ratio of 32.59 and a quick ratio of 32.39. Its debt-to-equity ratio stands at 0.64.

12-month forecast

$APGE price target

Apogee Therapeutics, Inc. daily closes and this analyst's $135 target. Not advice.

Analysts Set New Price Targets

On June 23, 2026, Deutsche Bank downgraded Apogee Therapeutics to a hold rating, setting a price target of $135. Citigroup also downgraded the stock to hold with the same target, while UBS followed suit with a similar downgrade and target. RBC Capital maintained its hold rating with a target of $135, and Canaccord Genuity also downgraded its rating to hold with a $135.11 target. The consensus rating for Apogee Therapeutics is a strong buy, with a mean price target of $119.50 based on 16 analyst opinions.

About Apogee Therapeutics

Apogee Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing novel biologics for treating various inflammatory and immunological conditions, including atopic dermatitis, asthma, and eosinophilic esophagitis. The company is working on several clinical-stage therapies, with Zumilokibart (APG777) in phase 2 trials for atopic dermatitis. Apogee was founded in 2022 and is led by CEO Dr. Michael Thomas Henderson.

Bottom Line

Investors are keeping a close eye on Apogee Therapeutics following Deutsche Bank's downgrade to a hold rating and the new price target of $135. While institutional investors like T. Rowe Price have significantly increased their holdings, the stock remains volatile. This analyst activity provides insights into market sentiment, although 13F filings are inherently backward-looking and may not reflect current positions.